Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16936176 | 0.86 | HDAC1 (0.71) | MAPTHDAC1HDAC8HDAC6MEN1 | |
| SCHEMBL11514576 | 0.85 | PLK1 (0.70) | MAPTNPC1ALDH1A1RAB9ARXFP1 | |
| SCHEMBL4158650 | 0.83 | HDAC1 (0.58) | MAPTHDAC1MEN1KMT2ANPC1 | |
| SCHEMBL9513479 | 0.83 | MAPT (0.80) | MAPTMEN1KMT2AAKR1C4AKR1C3 | |
| SCHEMBL15789123 | 0.83 | DHODH (0.72) | MAPTHDAC1HDAC8HDAC6MEN1 | |
| SCHEMBL24252964 | 0.83 | MAPT (0.66) | MAPTHDAC1HDAC8HDAC6MEN1 | |
| SCHEMBL29434785 | 0.83 | DHODH (0.72) | MAPTHDAC1HDAC8HDAC6MEN1 | |
| SCHEMBL2898181 | 0.83 | GAA (0.70) | MAPTHDAC1HDAC8HDAC6MEN1 | |
| SCHEMBL29175040 | 0.83 | SMN1; SMN2 (0.66) | MAPTHDAC1HDAC8HDAC6MEN1 | |
| SCHEMBL336750 | 0.82 | MAPT (0.68) | MAPTHDAC1HDAC8HDAC6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11160773-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2021-11-02 | — | — | US | disclosed |
| EP-2897185-B1 | Organic light-emitting device | SAMSUNG DISPLAY CO LTD (KR) | 2020-12-16 | — | — | EP | disclosed |
| EP-2897185-B1 | Organic light-emitting device | SAMSUNG DISPLAY CO LTD (KR) | 2020-12-16 | — | — | EP | disclosed |
| US-20200246282-A1 | Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2020-08-06 | — | — | US | disclosed |
| US-10653645-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2020-05-19 | — | — | US | disclosed |
| CN-104795504-B | Organic light emitting apparatus | 三星显示有限公司 | 2018-12-07 | — | — | CN | disclosed |
| US-10028922-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2018-07-24 | — | — | US | disclosed |
| US-10028922-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2018-07-24 | — | — | US | disclosed |
| WO-2018117493-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | 주식회사 두산 | 2018-06-28 | — | — | WO | disclosed |
| US-9543538-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-01-10 | — | — | US | disclosed |
| US-20130184352-A1 | METHOD OF TREATING GAUCHER DISEASE | MCMASTER UNIVERSITY (CA) | 2013-07-18 | — | — | US | disclosed |
| US-20130090388-A1 | METHOD OF TREATING GAUCHER DISEASE | MCMASTER UNIVERSITY (CA) | 2013-04-11 | — | — | US | disclosed |
| US-20130090388-A1 | METHOD OF TREATING GAUCHER DISEASE | MCMASTER UNIVERSITY (CA) | 2013-04-11 | — | — | US | disclosed |
| US-8124597-B2 | Method of treating gaucher disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2012-02-28 | — | — | US | disclosed |
| US-8124597-B2 | Method of treating gaucher disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2012-02-28 | — | — | US | disclosed |
| US-20120021487-A1 | METHOD OF TREATING GAUCHER DISEASE | MCMASTER UNIVERSITY (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20120021487-A1 | METHOD OF TREATING GAUCHER DISEASE | MCMASTER UNIVERSITY (CA) | 2012-01-26 | — | — | US | disclosed |
| WO-2009038695-A1 | METHOD OF TREATING GAUCHER DISEASE | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-03-26 | — | — | WO | disclosed |
| US-20090075960-A1 | Method of treating gaucher disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-03-19 | — | — | US | disclosed |
| US-20090075960-A1 | Method of treating gaucher disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075960-A1 | Method of treating gaucher disease | GBA1, GAA, GBA3 | MAPT 921/4885HDAC1 785/4885HDAC8 940/4885 |
| US-20200246282-A1 | Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase | GBA1, GBA3, GAA | MAPT 595/4885HDAC1 2500/4885HDAC8 2322/4885 |
| US-10653645-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | GBA1, GBA3, GAA | MAPT 595/4885HDAC1 2500/4885HDAC8 2322/4885 |
| US-11160773-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | GBA1, GBA3, GAA | MAPT 595/4885HDAC1 2500/4885HDAC8 2322/4885 |
| US-20130090388-A1 | METHOD OF TREATING GAUCHER DISEASE | GBA1, GAA, GBA3 | MAPT 921/4885HDAC1 785/4885HDAC8 940/4885 |
| US-10028922-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | GBA1, GBA3, GAA | MAPT 595/4885HDAC1 2500/4885HDAC8 2322/4885 |
| US-20130184352-A1 | METHOD OF TREATING GAUCHER DISEASE | GBA1, GAA, GBA3 | MAPT 921/4885HDAC1 785/4885HDAC8 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.